Clinical Trials Directory

Trials / Unknown

UnknownNCT00854932

Neonatal Procalcitonin Intervention Study

Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,600 (estimated)
Sponsor
Luzerner Kantonsspital · Academic / Other
Sex
All
Age
3 Days
Healthy volunteers
Not accepted

Summary

In neonates, clinical signs and symptoms associated with early-onset sepsis are non-specific and currently available tests have poor positive and negative predictive values. The investigators hypothesize that procalcitonin (PCT) has a reliable negative predictive values to allow a reduction in duration of empiric antibiotic therapy in suspected neonatal early-onset sepsis with unchanged outcome. This study is designed as a multi-center, prospective, randomized intervention trial. The duration of antibiotic therapy in the standard group is based on the attending physician's assessment of the probability of infection during hospitalisation. In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.

Detailed description

Detailed description according our pilot study (see reference). This trial is designed to exclude a difference in rate of re-infection or death greater than 2%. Assuming a 2% reinfection/death rate in each group, 770 patients are required for a power of 80% at alpha=0.05. To allow for some unevaluable cases 800 per group will be included. Based on the data of the pilot study (see reference), with a number of 770 per group a difference between mean antibiotic therapy durations of 10 hours can be detected at two-sided alpha of 0.05 with a power of 95%.

Conditions

Interventions

TypeNameDescription
OTHERProcalcitonin-guided decision makingIn the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.

Timeline

Start date
2009-06-01
Primary completion
2015-05-01
Completion
2016-08-01
First posted
2009-03-03
Last updated
2016-03-08

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00854932. Inclusion in this directory is not an endorsement.